Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer

収録刊行物

関連論文

もっと見る

詳細情報

  • CRID
    1370283692562104457
  • データソース種別
    • Crossref
ページトップへ